Potentiating the pulmonary vasodilatory effects produced by sildenafil

[...]we would like to comment on another study showing that a NO-releasing drug (DETA-nonoate) did not enhance the pulmonary vasodilator effects of sildenafil during PH-APE.5 Together, these recent studies suggest that NO-donors or the substrate for NO synthesis do not enhance the pulmonary vasodila...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Respiratory medicine 2007-05, Vol.101 (5), p.1041-1041
1. Verfasser:	Dias-Junior, Carlos A
Format:	Artikel
Sprache:	eng
Schlagworte:	Drug Therapy, Combination Humans Hypertension Hypertension, Pulmonary - drug therapy Nitric oxide Nitric Oxide - therapeutic use Piperazines - therapeutic use Pulmonary arteries Pulmonary/Respiratory Purines - therapeutic use Sildenafil Citrate Studies Sulfones - therapeutic use Vasodilator Agents - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	[...]we would like to comment on another study showing that a NO-releasing drug (DETA-nonoate) did not enhance the pulmonary vasodilator effects of sildenafil during PH-APE.5 Together, these recent studies suggest that NO-donors or the substrate for NO synthesis do not enhance the pulmonary vasodilatory effects produced by sildenafil during PH-APE without producing systemic effects.
ISSN:	0954-6111 1532-3064
DOI:	10.1016/j.rmed.2006.10.028